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Item of correspondence
Teriflunomide is a novel pyrimidine synthesis inhibitor which limits immune response by selectively 
blocking dihydroorotate dehydrogenase, required by rapidly dividing B and T lymphocytes [1]. It is 
indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most 
common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache 
(18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia 
(10% and 13%), and nausea (8% and 11%), respectively [2].
Although diarrhea is a frequent side effect, there is little known about the pathogenesis or the 
microscopic alterations. In a series of 100 patients treated with teriflunomide, 14 developed mild-to-
moderate diarrhea, which resolved within a month; however, 4 experienced prolonged diarrhea 
related to lactose intolerance confirmed by a positive lactose breath test and associated with the 
lactose present in the capsule [3]. A recent manuscript proposed the possibility of teriflunomide 
promoting a lymphocytic colitis pattern [4]. Finally, Duquette et al. also described a case of 
histologically acute and subacute colitis related to high teriflunomide blood concentration after 2 
years of treatment [5].
We report a case of colitis for which the pathology implicates teriflunomide therapy, despite the 
puzzling patient’s history. 
A 39-year-old female patient diagnosed with relapsing-remitting multiple sclerosis was treated with 
14 mg per os teriflunomide per day. The patient has not received other immunosuppressant or 
immunomodulatory drugs. Three years after the initiation of the therapy, the patient developed 
prolonged watery diarrhea with cramping abdominal pain. Clostridioides difficile (C. diff) was 
detected from a stool sample one month after the start of the symptoms. The symptomology 
stopped after the cassation of teriflunomide and appropriate antibiotherapy.
The colonoscopy showed few scattered non-bleeding aphthous ulcers in the ileum. The colonic 
mucosa was diffusely congested, erythematous and friable. Shallow ulcerations, up to 15 mm A
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diameter, were detected in a confluent and circumferential pattern from the rectum to the 
ascending colon. 
Terminal ileum and multistep colon biopsies were taken. Microscopically, there was no evidence of 
pseudomembranes, erupting “volcano” crypts, increased intraepithelial lymphocytosis, subepithelial 
collagen band, granuloma, microorganisms or vasculitis. The microscopy was very much suggestive 
of drug-induced colitis with multifocal crypt apoptosis and crypt withering combined with diffuse 
active inflammation and surface epithelial damage, minimal erosions, and reactive changes as well 
as cryptitis and crypt abscesses. Lamina propria lymphocytes, plasma cells, and eosinophil 
granulocytes were respectively moderately increased. Evidence of mild chronicity, including crypt 
architectural disarray, basal plasmacytosis with shortened crypts, and crypt dropout was also 
present (Figure 1, 2). Immunohistochemistry for cytomegalovirus (CMV) and adenovirus performed 
on multiple blocks yielded a negative result. 
This case is challenging on several fronts. Based on the morphologic changes, we suggest that 
teriflunomide, a pyrimidine synthesis inhibitor, may initiate mucosal injury in a way similar to the 
purine synthesis inhibitor mycophenolate by altering DNA synthesis that is not only required by 
rapidly dividing B and T lymphocytes but also to a certain extend by intestinal epithelium [1]. 
However, while neither the endoscopic nor the microscopic appearance was consistent with C. diff 
colitis, it raises the question of whether teriflunomide could synergistically promote C difficile 
infection.
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Figure 1. Histological image of descending colon biopsy. Note the active inflammation with crypt 
abscesses, and apoptosis of crypt epithelial cells (asterisk).
Figure 2. Histological image of sigmoid colon biopsy. Note the active inflammation with mild crypt 
architectural distortion, basal plasmacytosis, and the withering crypts.
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